{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:20:32Z","timestamp":1783099232252,"version":"3.54.6"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173743"],"award-info":[{"award-number":["82173743"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272742"],"award-info":[{"award-number":["82272742"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473233"],"award-info":[{"award-number":["82473233"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bmcl.2026.130666","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:07:34Z","timestamp":1776787654000},"page":"130666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of novel hydroxime-based NLRP3 inflammasome inhibitors with reduced hepatotoxicity"],"prefix":"10.1016","volume":"137","author":[{"given":"Wei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anhua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mochenxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuelin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyuan","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2026.130666_bb0005","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nm.3893","article-title":"Inflammasomes: mechanism of action, role in disease, and therapeutics","volume":"21","author":"Guo","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.bmcl.2026.130666_bb0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.abb.2019.05.023","article-title":"Structure, interactions and self-assembly of ASC-dependent inflammasomes","volume":"670","author":"de Alba","year":"2019","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.bmcl.2026.130666_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103815","article-title":"The entrenchment of NLRP3 inflammasomes in autoimmune disease-related inflammation","volume":"24","author":"Carnazzo","year":"2025","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.bmcl.2026.130666_bb0020","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41423-025-01275-w","article-title":"NLRP3 inflammasome in neuroinflammation and central nervous system diseases","volume":"22","author":"Xu","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.bmcl.2026.130666_bb0025","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13578-024-01256-y","article-title":"Role of NLRP3 inflammasome in central nervous system diseases","volume":"14","author":"Zhang","year":"2024","journal-title":"Cell Biosci"},{"key":"10.1016\/j.bmcl.2026.130666_bb0030","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41569-023-00946-3","article-title":"The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases","volume":"21","author":"Toldo","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.bmcl.2026.130666_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108545","article-title":"NLRP3 and cancer: pathogenesis and therapeutic opportunities","volume":"251","author":"Tengesdal","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmcl.2026.130666_bb0040","article-title":"Therapeutic potential of pharmacological targeting NLRP3 inflammasome complex in cancer","volume":"11","author":"Tezcan","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmcl.2026.130666_bb0045","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12964-023-01235-9","article-title":"Divergent functions of NLRP3 inflammasomes in cancer: a review","volume":"21","author":"Shadab","year":"2023","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.bmcl.2026.130666_bb0050","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/ard.2004.025577","article-title":"Expression and regulation of cryopyrin and related proteins in rheumatoid arthritis synovium","volume":"64","author":"Rosengren","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bmcl.2026.130666_bb0055","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41586-019-1769-z","article-title":"NLRP3 inflammasome activation drives tau pathology","volume":"575","author":"Ising","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2026.130666_bb0060","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41698-021-00154-7","article-title":"Dynamic roles of inflammasomes in inflammatory tumor microenvironment","volume":"5","author":"Jang","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.bmcl.2026.130666_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000354","article-title":"MCC950\/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition","volume":"17","author":"Vande Walle","year":"2019","journal-title":"PLoS Biol"},{"key":"10.1016\/j.bmcl.2026.130666_bb0070","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41586-019-1295-z","article-title":"Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome","volume":"570","author":"Sharif","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2026.130666_bb0075","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/s41423-023-01107-9","article-title":"Integrated NLRP3, AIM2, NLRC4, pyrin inflammasome activation and assembly drive PANoptosis","volume":"20","author":"Oh","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.bmcl.2026.130666_bb0080","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.bmcl.2026.130666_bb0085","article-title":"MCC950 ameliorates acute liver injury through modulating macrophage polarization and myeloid-derived suppressor cells function","volume":"8","author":"Yan","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.bmcl.2026.130666_bb0090","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1021\/acs.jmedchem.4c02759","article-title":"Discovery of DFV890, a potent sulfonimidamide-containing NLRP3 inflammasome inhibitor","volume":"68","author":"Shen","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130666_bb0095","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1021\/acs.jmedchem.3c00175","article-title":"Novel aryl sulfonamide derivatives as NLRP3 inflammasome inhibitors for the potential treatment of cancer","volume":"66","author":"Albanese","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130666_bb0100","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.1021\/acs.jmedchem.4c02813","article-title":"Discovery of novel sulfonylurea NLRP3 inflammasome inhibitor for the treatment of multiple inflammatory diseases","volume":"68","author":"Liu","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130666_bb0105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41573-023-00822-2","article-title":"Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets","volume":"23","author":"Vande Walle","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2026.130666_bb0110","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/toxsci\/kfv152","article-title":"Setting clinical exposure levels of concern for drug-induced liver injury (DILI) using mechanistic in vitro assays","volume":"147","author":"Shah","year":"2015","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.bmcl.2026.130666_bb0115","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.26208","article-title":"High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury","volume":"58","author":"Chen","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.bmcl.2026.130666_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175091","article-title":"Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome","volume":"928","author":"Li","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bmcl.2026.130666_bb0125","doi-asserted-by":"crossref","first-page":"8289","DOI":"10.1021\/acs.jmedchem.2c00170","article-title":"Crystallography-guided optimizations of the Keap1-Nrf2 inhibitors on the solvent exposed region: from symmetric to asymmetric naphthalenesulfonamides","volume":"65","author":"Liu","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130666_bb0130","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41586-022-04467-w","article-title":"Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3","volume":"604","author":"Hochheiser","year":"2022","journal-title":"Nature"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26001332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26001332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T16:41:27Z","timestamp":1783096887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X26001332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":26,"alternative-id":["S0960894X26001332"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130666","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel hydroxime-based NLRP3 inflammasome inhibitors with reduced hepatotoxicity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130666","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130666"}}